| Value | ₹1.00 Cr |
|---|---|
| Execution period | 2 years |
NSE filing, NSE: ZIMLAB. Summary written from the filing by ALFA Finder's alert engine.
Zim Laboratories Ltd: key numbers
- Share price
- ₹136.29
- Market cap
- ₹731.3 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 197.9×Sector 45.9×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.
Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Other employee stock options announcements
All →Niva Bupa Health Insurance Company Employee Stock Options
Niva Bupa allotted 9,89,450 equity shares to employees on exercise of ESOP options under its 2020 and 2024 schemes. Paid-up capital rose to Rs. 18,50,63,41,530.
Meesho Employee Stock Options
Meesho allotted 21,43,590 equity shares to employees on exercise of ESOP 2024 options. No exercise price or consideration is disclosed in the filing.
Studds Accessories Employee Stock Options
Studds Accessories granted 1,30,000 ESOPs to eligible employees under its 2026 scheme at an exercise price of Rs 334.90. Options vest over time, converting to equity shares on exercise.
Poonawalla Fincorp Employee Stock Options
Poonawalla Fincorp allotted 30,773 equity shares under its employee stock option schemes on 31 October 2026. The shares rank pari passu with existing equity.
Eveready Industries India Employee Stock Options
Eveready Industries granted 48,000 stock options to eligible employees under its ESOP 2026 plan, approved by the NRC on 31 October 2026. The filing is an employee stock option grant intimation with no cash consideration stated.
Max Estates Employee Stock Options
Max Estates allotted 632 equity shares to an option holder under its ESOP Plan 2023. The allotment raises paid-up capital; no transaction price is stated.